Diseases Commons^™

Soluble Neprilysin And Long-Term Clinical Outcomes In Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Retrospective Cohort Study, Ik Jun Choi, Sungmin Lim, Youngdeok Hwang, Dongjae Lee, Won Jik Lee, Kwan Yong Lee, Mi-Jeong Kim, Doo Soo Jeon

Publications and Research

Background: Neprilysin has an essential role in regulating fluid balance and vascular resistance, and neprilysin inhibitors have shown beneficial effects in patients with heart failure. However, the potential predictive value of neprilysin levels as a biomarker for cardiovascular risk remains unclear. The aim of this study was to assess the prognostic value of soluble neprilysin (sNEP) levels in patients with ischemic heart disease.

Methods: Neprilysin levels were measured in 694 consecutive patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). These patients were classified into two groups according to their serum levels of neprilysin and categorized into the …

The Efficacy Of Adding Eicosapentaenoic Acid To Statin Monotherapy In The Prevention Of Acute Coronary Syndrome In Patients With Coronary Artery Disease, Carlo Escudero

Capstone Showcase

Introduction: Coronary artery disease (CAD) is a chronic medical condition caused by the buildup of plaque within the coronary artery endothelium. If left untreated it can progress to an acute coronary syndrome (ACS) which can lead to myocardial ischemia and death. Statins are lipid lowering agents used in clinical practice for the medical management of CAD. However, incidence of major adverse cardiovascular (CV) events still occurs despite optimal statin therapy. Currently eicosapentaenoic acid (EPA) has been promoted to be effective when added to statin therapy in lowering the incidence of CV events in patients with hypercholesterolemia. This paper will address …